UR+AIMS Gout Wearable Skin Uric Acid Monitor Study
Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Dec 15, 2023
Trial Information
Current as of July 21, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The UR+AIMS Gout Wearable Skin Uric Acid Monitor Study is a clinical trial that aims to learn more about how a new skin patch can help monitor uric acid levels in people with gout. Gout is a type of arthritis that happens when the body has too much uric acid, which can cause painful swelling in the joints. In this study, 15 participants with gout will take part in a special meal at the UCLA Human Nutrition Center and will then use the skin patch for a week to measure their uric acid levels and other substances in their body.
To be eligible for this study, participants must be over 18 years old and have a diagnosis of gout. Some participants will not be on any medication to lower uric acid for at least six months, while others will be on stable medication that hasn’t changed in the last month. It's important to note that some people may not be able to participate due to specific health conditions or allergies. If chosen, participants can expect to follow a structured meal plan and track their uric acid levels with the patch over the week. This trial is not yet recruiting, but it represents an exciting opportunity to improve gout management through innovative technology.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age \> 18 with diagnosis of gout (screening positive ACR/EULAR Gout Classification Criteria - see screening survey) and eGFR \> 60 (within the last 12-months).
- • 2. For the 10 patients with gout off urate-lowering therapy (ULT) \[no Allopurinol, febuxostat, or probenecid prescription within the last 6-months\] and serum urate (SU) \> 7 mg/dL (within the last 12-months).
- • 3. For the 5 patients with gout on urate-lowering therapy (ULT) \[no dose change within the last 30 days\].
- Exclusion Criteria:
- • 1. Contraindications to miosis, which include acute iritis, narrow-angle glaucoma
- • 2. Known Hypersensitivity to pilocarpine hydrochloride
- • 3. Pupillary block glaucoma (ophthalmic solution)
- • 4. Subjects reporting any allergy to glue or latex or any allergy to food that will be provided in the study (sardines in extra virgin olive oil and Sprite).
About University Of California, Los Angeles
The University of California, Los Angeles (UCLA) is a prestigious academic institution renowned for its commitment to research and innovation in the biomedical field. As a clinical trial sponsor, UCLA leverages its cutting-edge facilities, expert faculty, and collaborative environment to advance medical knowledge and improve patient care. The university is dedicated to conducting rigorous clinical research that adheres to the highest ethical standards, aiming to translate scientific discoveries into effective therapies and interventions. Through its diverse array of clinical trials, UCLA seeks to address critical health challenges while fostering the development of future healthcare leaders.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Los Angeles, California, United States
Patients applied
Trial Officials
John FitzGerald, MD
Principal Investigator
University of California, Los Angeles
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported